Goldman Sachs
TBIO

Goldman Sachs’s Telesis Bio, Inc. Common Stock TBIO Stock Holding History

Goldman Sachs’s Portfolio TBIO Stock Details TBIO Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2022
Q4 		– Sell
-921
Closed -$28K – 6328
2022
Q3 		$28K Sell
921
-568
-38% -$20K ﹤0.01% 5878
2022
Q2 		$48K Sell
1,489
-7,097
-83% -$490K ﹤0.01% 6037
2022
Q1 		$830K Buy
8,586
+7,292
+564% +$1.11M ﹤0.01% 4974
2021
Q4 		$252K Buy
+1,294
New +$201K ﹤0.01% 5768
2021
Q3 		– Sell
-3,706
Closed -$1.47M – 6576
2021
Q2 		$1.47M Buy
+3,706
New +$1.31M ﹤0.01% 4471

Other funds holding TBIO

NV
Northpond Ventures Bethesda, Maryland $43.7M AUM 27.27% 1-Year Est. Return
PCM
Penn Capital Management Philadelphia, Pennsylvania $1.58B AUM 81.2% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
Millennium Management
Millennium Management New York $240B AUM 35.51% 1-Year Est. Return
PM
Penbrook Management New York $157M AUM 46.57% 1-Year Est. Return
BCM
Bridgeway Capital Management Houston, Texas $4.97B AUM 44.96% 1-Year Est. Return
Renaissance Technologies
Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
Two Sigma Investments
Two Sigma Investments New York $124B AUM 33.93% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Goldman Sachs's TBIO Position: Q4 2022 in Review

Goldman Sachs sold out of Telesis Bio, Inc. Common Stock (TBIO) in Q4 2022, closing a stake of 921 shares — an estimated $28K sold.

Goldman Sachs first reported a position in TBIO in Q2 2021 and held it in 5 quarters. The position peaked at $1.47M in Q2 2021. 24 funds tracked by Wall St. Rank hold TBIO as of Q4 2022.

  • Goldman Sachs reported no remaining Telesis Bio, Inc. Common Stock position as of Q4 2022 after selling out during the quarter.
  • Goldman Sachs sold 921 Telesis Bio, Inc. Common Stock shares in Q4 2022, an estimated $28K.
  • Goldman Sachs first reported a position in Telesis Bio, Inc. Common Stock in Q2 2021 and held it in 5 quarters.
  • Goldman Sachs's Telesis Bio, Inc. Common Stock position peaked at $1.47M in Q2 2021.
  • 24 funds tracked by Wall St. Rank held Telesis Bio, Inc. Common Stock as of Q4 2022.

Based on Goldman Sachs's 13F filing for Q4 2022, filed 13 Feb 2023.